EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Josef S Smolen, Robert B M Landewé, Johannes W J Bijlsma...
https://pubmed.ncbi.nlm.nih.gov/31969328/Actively Recruiting
Led by Horus University · Updated on 2026-05-12
90
Participants Needed
1
Research Sites
4 weeks
Total Duration
Rheumatoid arthritis is a chronic autoimmune disease causing joint pain, swelling, and disability despite treatment with standard disease-modifying antirheumatic drugs DMARDs. Researchers are evaluating whether adding roflumilast or desloratadine to standard DMARD therapy can better control disease activity and inflammation in patients with persistent symptoms. This phase 2 randomized, double-blind, placebo-controlled trial aims to assess the safety and effectiveness of these add-on treatments for rheumatoid arthritis over a three-month period. Participants will be randomly assigned to one of three groups receiving roflumilast, desloratadine, or placebo, each added to their usual DMARD therapy. Treatments are given orally and continue for three months. The studys design includes parallel groups to compare each add-on treatment against placebo while patients maintain their standard care. During the study, participants will undergo clinical assessments including disease activity scoring DAS28, blood tests to measure inflammatory markers, and patient-reported outcome questionnaires. Safety and tolerability will be monitored throughout the 12-week treatment. Researchers will track changes from baseline to 12 weeks to determine the impact of the treatments. Participation lasts about three months, with regular evaluations to monitor progress and safety.
CONDITIONS
Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis
A
Amira Mashaly
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Horus University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 months
Participants receive roflumilast, desloratadine, or placebo as add-on therapy to their standard rheumatoid arthritis treatment.
Visits during the 3-month treatment period for clinical assessments and monitoring
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Josef S Smolen, Robert B M Landewé, Johannes W J Bijlsma...
https://pubmed.ncbi.nlm.nih.gov/31969328/Horus University
Lead Sponsor